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Improving outcomes for women with epithelial ovarian cancer is a major health issue worldwide as
5-year survival has not improved significantly over the last two decades.
The urgent need to increase our understanding of high-grade serous ovarian cancer (HG-SOC)
led to it being chosen for the pilot project of The Cancer Genome Atlas (TCGA) and the genomes of
over 400 HG-SOC samples are now freely accessible for interrogation. These data are being used for
the discovery of biomarkers as well as the generation of hypotheses to understand the natural history
of this malignancy and develop effective targeted therapies. In this Research Topic, Lisowaska and
colleagues used gene expression profiling to identify that reduced expression of CLASP1, a regulator
of microtubule dynamics essential for mitotic cell cycling was positively associated with survival,
either overall or disease free (1). Their data clearly highlighted that different histological subtypes of
ovarian cancer had very different molecular signatures, although undifferentiated and high-grade
serous ones were indistinguishable. These results are consistent with other findings that together
have led to the understanding that epithelial ovarian cancer (EOC) is not a single entity but rather
a number of distinct malignancies with different etiologies and molecular aberrations. Of these,
HG-SOC is the most aggressive and common, accounting for 60–70% of all cases of ovarian cancer.
Notwithstanding the unprecedented in silico resource now available via TCGA and other web-
based portals, research in HG-SOC is hampered on a number of fronts. Comparison of results
from cancerous or cancer-associated stromal cells with each non-cancerous (normal) equivalent is a
fundamental research question, but what to use for normal cells is unclear. Recent evidence suggests
that HG-SOC has its origins in the secretory cells located in the fimbrial end of the fallopian tube.
This is contrary to the prevailing notion that HG-SOC arises from the epithelium lining the ovary
and inclusion cysts. The contribution of each site to serous ovarian carcinogenesis is currently under
debate. Jones andDrapkin recount the evolution of evidence for each site of origin and review the use
and limitations of primary cell culture model systems developed from each site (2). In support of an
ovarian surface epithelial (OSE) origin for HG-SOC,McCloskey and colleagues describe the tumor-
initiating characteristics of a novel spontaneously transformed mouse OSE cell line (3). Ahmed and
Stenvers draw attention to ascites, an underutilized yet readily accessible source of primary cancer
cells from EOC patients and provide a detailed review of its use as a clinically relevant model system
(4).Differentmethods of isolation and culture of primary ovarian cancer tumor cells fromascites and
other sources are reviewed by Cunnea and Stronach who also advocate for universal standardized
protocols for improved reproducibility and interpretation of results between studies (5).
In conjunction with the development of new cell models is the move to three-dimensional (3D)
culture conditions. 3D culture systems feature in several articles in this Research Topic indicating the
enthusiasm for this culture type and recognition of the deficiencies of themonolayer systems (2, 5, 6).
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It is hoped that models with more physiologically relevant
microenvironments will lead to increased clinical translation of
findings. 2D and 3D culture systems are compared by Fuller and
Howell and the characteristics of the different matrices available
reviewed (6).
Resistance to platinum therapy continues to be a major issue
in HG-SOC (5, 7, 8). Cunnea and Stronach review the currently
available immortalized cell lines in the context of sensitivity and
resistance to platinum and highlight deficiencies in in vitro devel-
opment of treatment resistance (5). In particular, they illustrate
the power of having serial cell lines from the same patient which
have been able to show that the development of treatment resis-
tance was due to the selection of resistant sub-clones rather than
evolution of new lineages. They note the need for more such
matched cell lines, which is now one of the goals of the European
OCTIPS (Ovarian cancer therapy – innovative models prolong
survival) consortium.
In light of the inevitable development of platinum resistant
or refractory disease (7), new strategies and agents to reduce
tumor burden and improve patient outcomes are in high demand.
Essential for preclinical development are accurate and robust EOC
model systems. The current status of EOC models specifically for
preclinical development is reviewed by Konstantinopoulos and
Matulonis (9). Different theories for overcoming platinum resis-
tance are detailed in this Research Topic. Evidence from genetic
and functional studies of HG-SOC point to the homologous DNA
repair (HR) system, in particular BRCA1 and BRCA2, as criti-
cal determinants of response to platinum therapy. Wiedemeyer
and colleagues discuss the concept of disrupting HR capacity
via BRCA1/2 to reverse platinum resistance in BRCA-proficient
cancers (8). They provide a comprehensive overview of available
agents and the genetic aberrations targeted by these agents illus-
trating how rational therapeutic combinations may be designed
to prevent or delay the onset of platinum resistance in HG-SOC.
Alternative theories of platinum resistance are proposed by Chien
and colleagues that also take into account the paradoxical recur-
rence of platinum sensitivity observed in patients with HG-SOC
(7). They present the cancer stem cell theory for both the devel-
opment of resistance and sensitivity upon recurrence and high-
light the involvement of specific components of the extracellular
matrix in the establishment of stem cell niches. Based on this evi-
dence, they suggest that cancer cells are not intrinsically resistant
to platinum but, rather, acquire extracellular matrix-dependent
platinum resistance.
Targeting cancer stem cells is the basis of a new therapy iden-
tified by Abubaker and colleagues (10). They observed that pacli-
taxel treatment enhanced the expression of cancer stem cell-like
markers in surviving cancer cells in vivo and coincided with sig-
nificant activation of the JAK2/STAT3 pathway. In their research
manuscript, they report the efficacy of concurrent paclitaxel and
JAK2/STAT3 pathway inhibitor, CYT387, in a xenograft model of
HG-SOC.
Having a familial BRCA1/2 mutation remains the best defined
risk factor forHG-SOC. The search forHG-SOCprecursor lesions
led to the discovery of P53 signatures, serous tubal intraepithe-
lial lesion (STILs) and serous tubal intraepithelial carcinomas
(STICs) all in the fallopian tubal epithelium, implicating this tissue
as a site of origin for HG-SOC. George and Shaw provide a
critical review of the literature related to these findings, noting
that P53 signatures are found with similar frequencies in BRCA-
mutation carriers and non-carriers, and that STILs and STICS are
uncommon and identified with poor reproducibility (11). They
review what is known regarding the involvement of hormones
in HG-SOC development with specific reference to the altered
reproductive physiology in BRCA-mutation carriers and propose
that the combination of ovulation-induced chronic inflammation
coupled with BRCA-mutations may predispose the development
of precancerous lesions leading to HG-SOC.
While the changing notion of the site of origin of HG-SOC
is critical for understanding the molecular mechanisms of ovar-
ian cancer, it also has “real world” implications for prophy-
lactic strategies for women with familial BRCA mutations or a
strong family history of breast and ovarian cancer. Shenenberg
and Mitchell review the molecular evidence providing rationale
for risk-reducing bilateral salpingo-oophorectomy versus bilateral
salpingectomy versus bilateral salpingectomy and delayed bilateral
oophorectomy (12). This is elegantly balanced against quality of
life issues that each individual faces when determining which
risk-reducing procedure if any, is most appropriate for them.
Non-surgical alternatives that may reduce risk and advances in
diagnostic imaging for improved early detection, including cur-
rent research assessing folate receptor α and HER-2 for tumor-
specific imaging are reviewed by Ohman and colleagues (13).
Understanding disease development requires models of tumor
progression and is best addressed by spontaneous mouse models.
However, there is a paucity of reproducible spontaneous animal
models of HG-SOC. This may be partly explained by the lack of
promoters to drive genetic changes in the cell of origin of this dis-
ease. However, circumventing this technical difficulty by surgical
delivery of Cre recombinase has not always delivered the expected
outcomes. Does this again relate to the cell of origin? Newmodels
for the study of HG-SOC are being generated to accommodate the
changing view of the cell of origin and enablemonitoring of tumor
progression. House and colleagues and others provide overviews
of the results of using different methods to direct genetic changes
to the OSE and FTE (2, 13, 14). Smith and colleagues discuss
the importance of including menopausal physiology in mouse
models of EOC and propose the germ cell-deficient Wv mice
(c-kit mutant) as a background strain for breeding with relevant
genetically engineered changes (15).
While grafted models of HG-SOC are not suitable for assessing
early stage disease, their faster time course and the ability to
easily add in reporters for in vivo imaging provide advantages
over the spontaneous models. House and colleagues review the
few reported syngeneic models of HG-SOC as well as the imaging
modalities available for in vivo studies (14). The characterization
of an FVB/N strain syngeneic model of HG-SOC by McCloskey
and colleagues, reported for the first time in this Research Topic,
thus has the potential to be an exciting and useful addition to the
armory of reagents available for ovarian cancer research (3).
Xenografts are the most utilized in vivo platform for many
cancers, including EOC. However, it is well recognized that they
have deficiencies in recapitulating the tumors they represent.
These include the loss of fidelity through in vitro culture, lack of
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cellular heterogeneity and lack of an intact immune system. The
advent of patient-derived xenograft (PDX) models was aimed at
overcoming two of these deficiencies by using pieces of patient
tumors that had never been cultured in vitro and that retained the
microenvironment of the original tumor. PDX models are aimed
primarily at testing drug responses. The site of implantation of
PDXs can alter the rate of engraftment as well as the characteristics
of the model. The advantages and disadvantages of the different
sites of implantation are discussed by Scott and colleagues as
part of their review of PDX model systems that have been trialed
for EOC (16). They and others also assess the utility of PDX
models as preclinical models for trialing new therapies for EOC
(2, 13, 14, 16).
The rapid acceptance of PDXs as preclinical models under-
scores the increasing awareness of the contribution of the
microenvironment to the pathogenesis and progression of cancer.
An overview of the different components of the microenviron-
ment such as proteases and extracellular matrix and their roles
in promoting invasion and metastasis in EOC is presented by
Davidson and colleagues (17). Dissemination of this cancer
by shedding of cells into the peritoneum is a major route of
metastases and involves interactions between cancer cells and
adipocytes, endothelial cells, fibroblasts, mesenchymal stem cells,
macrophages, and other immune cells. The microenvironment
of the peritoneal cavity that makes it highly conducive to
carcinomatosis and the therapeutic implications of targeting the
heterotypic cellular interactions within the peritoneum are the
focus of the review byNaora (18).Within the immune population,
tumor-associated macrophages represent the most abundant
infiltrating immune cell in human ovarian tumors and ascites.
They display a unique activation profile in ovarian tumors and
are able to create an immunosuppressive microenvironment,
allowing tumors to evade immune detection and promoting
tumor progression. This cell type is the focus of mini-review by
Colvin (19).
In summary, this Research Topic showcases our current
understanding of a number of key areas in EOC. It has
a strong focus on model systems given the critical impor-
tance of having accurate systems and the particular difficulties
and dilemmas faced especially in the development of in vivo
models.
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